Scholar Rock
SRRK
Market cap $2.68B

29.63 USD

-0.33

1.10%

Updated Oct 22, 10:49 AM EDT

1 day

-1.10%

5 days

3.57%

1 month

241.75%

3 months

221.37%

6 months

111.64%

Year to date

69.31%

1 year

293.49%

5 years

215.21%

About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Employees: 150

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

278% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $337K

55% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 44

14% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 28

3% more funds holding

Funds holding: 159 [Q1] → 163 (+4) [Q2]

2.13% less ownership

Funds ownership: 108.6% [Q1] → 106.47% (-2.13%) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

53% less capital invested

Capital invested by funds: $1.5B [Q1] → $707M (-$794M) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

39%

downside

Avg. target

$34

13%

upside

High target

$42

42%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Piper Sandler Allison Bratzel 89% 1-year accuracy 8 / 9 met price target	42%upside $42	Overweight Maintained	15 Oct 2024
JP Morgan Tessa Romero 79% 1-year accuracy 11 / 14 met price target	5%upside $31	Overweight Maintained	14 Oct 2024
BMO Capital Etzer Darout 60% 1-year accuracy 15 / 25 met price target	28%upside $38	Outperform Maintained	11 Oct 2024
HC Wainwright & Co. Andres Maldonado 72% 1-year accuracy 21 / 29 met price target	18%upside $35	Buy Maintained	8 Oct 2024
Wedbush David Nierengarten 49% 1-year accuracy 25 / 51 met price target	25%upside $37	Outperform Maintained	7 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 15 articles about SRRK published over the past 30 days

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that on October 16, 2024, the underwriters of its previously announced underwritten public offering of common stock and pre-funded warrants, which closed on October 10, 2024,.

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Zacks Investment Research

Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?

Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 23,500 shares of its common stock to two newly hired employees, consisting of inducement stock options to purc.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Motley Fool

Here's Why Everybody's Talking About Scholar Rock Right Now

Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.

Here's Why Everybody's Talking About Scholar Rock Right Now

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 10,265,488 shares of its common stock at a public offering price of $28.25 per share and, in lieu of common stock to.

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Zacks Investment Research

SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The positive results indicate that the apitegromab monoclonal antibody significantly improves motor function in patients.

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst.

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $275 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warra.

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip

US stocks struggled on Monday, pulling back after gains in the previous session as rising oil prices and higher interest rates dampened market sentiment. The Dow Jones Industrial Average dropped 441 points, or 1%, while the S&P 500 fell 1%, and the Nasdaq Composite lost 1.1%.

Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip

See News Rankings

Charts implemented using Lightweight Charts™